Por: Politico Health December 30, 2022
The FDA’s collaboration with Biogen, the maker of a controversial Alzheimer’s drug, before it granted the product accelerated approval was “atypical” and ran afoul of the agency’s protocol for documenting interactions with drug companies, according to a joint House Oversight and Energy and Commerce Democratic staff report released today. The panels began investigating Aduhelm’s approval and pricing in June 2021, just weeks after it... + full article
The Advocate USA Health January 02, 2023
What is Alzheimer’s disease?German neurologist Dr. Alois Alzheimer first identified this neurological disorder in 1906 while studying the pathology of a woman he had treated for an unusual mental illness.While examining her brain after her death, Alzheimer noticed marked... + más
How To Spot The Early Signs Of Alzheimer's | Newsweek
Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes
ABC News USA Health December 30, 2022
WASHINGTON -- The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.”The 18-month investigation by two House committees detailed... + más
FDA approves Alzheimer's drug that slowed cognitive decline in clinical trial | CNBC
10 WBNS USA Nation December 30, 2022
WASHINGTON — The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed... + más
Alzheimer's drug trial shown to slow cognitive decline in long fight against dementia | CNBC
Associated Press USA Politics December 30, 2022
WASHINGTON (AP) — The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.”The 18-month investigation by two House committees... + más
WPLG Local 10 USA Politics December 30, 2022
WASHINGTON – The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.”The 18-month investigation by two House committees detailed... + más
Los Angeles Times USA Science December 30, 2022
The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed “atypical... + más
Probe: Alzheimer's drug approval 'rife with irregularities' | ABC News
Probe: Alzheimer's drug approval 'rife with irregularities' | WPLG Local 10
NBC 6 South Florida USA World December 30, 2022
Adam Glanzman Bloomberg Getty Images The ’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed... + más
Alzheimer's drug approval by FDA 'rife with irregularities,' probe finds | Los Angeles Times
About iurex | Privacy Policy | Disclaimer |